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MaravirocWhile CCR5 is the principal coreceptor used by macrophage (M)-tropic HIV-1, not all primary CCR5-using
(R5) viruses enter macrophages efﬁciently. Here, we used functionally-diverse R5 envelope (Env) clones to
characterize virus-cell interactions important for efﬁcient CCR5-mediated macrophage entry. The magnitude
of macrophage entry by Env-pseudotyped reporter viruses correlated with increased immunoreactivity of
CD4-induced gp120 epitopes, increased ability to scavenge low levels of cell-surface CCR5, reduced
sensitivity to the CCR5 inhibitor maraviroc, and increased dependence on speciﬁc residues in the CCR5 ECL2
region. These results are consistent with an altered and more efﬁcient mechanism of CCR5 engagement.
Structural studies revealed potential alterations within the gp120 V3 loop, the gp41 interaction sites at the
gp120 C- and N-termini, and within the gp120 CD4 binding site which may directly or indirectly lead to more
efﬁcient CCR5-usage. Thus, enhanced gp120-CCR5 interactions may contribute to M-tropism of R5 HIV-1
strains through different structural mechanisms.at Centre for Virology, Burnet
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Human immunodeﬁciency virus type 1 (HIV-1) enters cells via
interaction of the viral envelope glycoproteins (Env) with CD4 and a
coreceptor. The Env is organized into trimers on virions and consists of
the gp120 surface and gp41 transmembrane subunits. HIV-1 entry into
cells is initiated by a high afﬁnity interaction between gp120 and CD4,
which induces a conformational change in gp120 that exposes the
binding site for a chemokine coreceptor, either CCR5 or CXCR4
[reviewed in (Doms, 2000; Doms and Trono, 2000)]. Currentmodels of
gp120 binding to coreceptor suggest the gp120 V3 loop interacts
principally with the coreceptor second extracellular loop (ECL2)
region, while the gp120 bridging sheet formed between the C1, C2 andC4 domains of gp120 after CD4 binding interacts with the coreceptor
N-terminus (Brelot et al., 1999; Cormier andDragic, 2002; Farzan et al.,
1999; Huang et al., 2005). While the coreceptor N-terminus and ECL2
region appear to be important for gp120-coreceptor binding, the ECL1
andECL3 regionsmay also inﬂuence coreceptor function (Doranz et al.,
1997, 1999; Farzan et al., 1998). The interaction of CD4-bound gp120
with coreceptor induces additional conformational changes in gp120,
which leads to a structural rearrangement in gp41 that enables fusion
and virus entry.
The tropism of HIV-1 for particular target cell populations in
different tissue compartments is inﬂuenced by the coreceptor used by
HIV-1 Env for virus entry [reviewed in (Gorry et al., 2004)].
Macrophage (M)-tropic HIV-1 viruses primarily uses CCR5 (R5) as a
coreceptor (Alkhatib et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996), whereas T-cell tropic viruses
use CXCR4 (X4) (Feng et al., 1996). Dual-tropic viruses can use both
coreceptors (R5X4) (Collman et al., 1992; Yi et al., 1999). Thus, the
coreceptor speciﬁcity of primary HIV-1 isolates is frequently used to
deﬁne cellular tropism; for example, R5 viruses are often collectively
grouped as M-tropic viral strains (Gorry et al., 2004). However, CCR5
270 J. Sterjovski et al. / Virology 404 (2010) 269–278usage by HIV-1 is neither necessary nor sufﬁcient for M-tropism.
Several studies have demonstrated the presence of non-M-tropic R5
viruses, which were replication competent in primary CD4+ T-cells
but which could not productively infect monocyte-derived macro-
phages (MDM) (Gorry et al., 2001; Gray et al., 2005; Li et al., 1999;
Peters et al., 2004, 2006, 2008). Thus, while CCR5 may be the main
coreceptor forHIV-1 entry intoMDM,not all R5 viruses areM-tropic. In
addition, some highly M-tropic primary HIV-1 strains use CXCR4 for
entry into MDM (Gorry et al., 2001; Gray et al., 2009). Therefore, the
viral determinants that underlie HIV-1 tropism for macrophages are
signiﬁcantlymore complex than the coreceptor speciﬁcity of the virus.
In addition to variations in the level of M-tropism, primary R5 HIV-1
strains have tremendous diversity in a number of other pathophysio-
logical phenotypes including cytopathicity for CD4+T-cells both in vitro
(Kwa et al., 2003;Wade et al., 2010) and in vivo (Berkowitz et al., 1998;
Fais et al., 1999; Scoggins et al., 2000), fusogenicity (Sterjovski et al.,
2007), viral ﬁtness (Borggren et al., 2008; Repits et al., 2005, 2008), and
sensitivity to virus inhibition by β-chemokines (Borggren et al., 2008;
Jansson et al., 1996, 1999; Koning et al., 2003; Repits et al., 2005, 2008)
and HIV-1 fusion/entry inhibitors (Gorry et al., 2001, 2002; Gray et al.,
2005; Repits et al., 2005; Sterjovski et al., 2007; Sterjovski et al., 2006). In
addition, primary R5 HIV-1 strains have diversity in the exposure of the
CD4 binding site (CD4bs) in gp120 which has been shown to inﬂuence
the level ofM-tropism (Duenas-Decampet al., 2009;Dunfee et al., 2006,
2007, 2009; Martin et al., 2001; Martin-Garcia et al., 2005; Peters et al.,
2004, 2008; Thomas et al., 2007), and suggested to inﬂuence the
mechanism and efﬁciency of CCR5 usage (Dunfee et al., 2006).
Although the aforementioned studies indicate that exposure of the
gp120 CD4bs and subsequent enhanced CD4 binding contributes to
M-tropism of R5 Envs, other studies suggest that an augmented
gp120-CCR5 interaction may also be important for efﬁcient macro-
phage entry (Gorry et al., 2001, 2002; Gray et al., 2005). Augmented
gp120-CCR5 interactions may occur in tandem with- or independent
from enhanced CD4 binding (Gorry et al., 2002). In this study, we
characterized alterations in the efﬁciency and mechanism of CCR5
engagement that contribute to efﬁcient macrophage entry of R5 Envs
derived from primary HIV-1 isolates.Results and Discussion
Diversity in the ability of primary R5 Envs to enter macrophages
The R5 Envs selected for this study were derived from primary
HIV-1 isolates and exhibit diversity in a number of phenotypesFig. 1. Primary R5 Envs vary in their ability to enter macrophages. Monocyte-derived
pseudotyped with an alternative control Env (A) or primary R5 Env (B) as described in Mate
the same preparations of reporter virus in JC53 cells, as described previously (Peters et al., 20
5 independent experiments using MDM derived from 5 different donors. Error bars represeincluding cell-cell fusion activity, entry kinetics, sensitivity to the
fusion inhibitor T-20, and sensitivity to neutralizing antibodies
(Sterjovski et al., 2007), indicating a broad spectrum of Env function.
Since variation in the ability of primary R5 viruses to enter
macrophages occurs principally at the virus entry level (Duenas-
Decamp et al., 2009; Gorry et al., 2001; Gray et al., 2005; Peters et al.,
2006, 2008), we reasoned that these Envs may have diversity in their
ability to enter macrophages efﬁciently and thus, be valuable reagents
to probe the mechanisms contributing to CCR5-mediated M-tropism.
We therefore determined the ability of luciferase reporter viruses
pseudotyped with an alternative R5 Env to enter MDM (Fig. 1). As
controls, we used luciferase reporter viruses pseudotyped with the
highly M-tropic R5 ADA, YU-2 or JR-FL Envs, the non-M-tropic X4
HXB2 Env, or the non-M-tropic R5 JR-CSF Env. As expected (Peters
et al., 2006), ADA, YU-2 and JR-FL Envs showedhigh levels of entry into
MDM, whereas the HXB2 and JR-CSF Envs entered MDM very
inefﬁciently (Fig. 1A). The primary R5 Envs showed considerable
diversity in their ability to enter MDM, and comprise Env variants
ranging from those that have very inefﬁcientMDMentry, similar to the
non-M-tropic JR-CSF Env, to one variant that entersMDMas efﬁciently
as the highly M-tropic ADA and JR-FL Envs (NB23-C3) (Fig. 1B). The
non-normalized luciferase values are summarized in Supplementary
Table 1. Thus, we established a panel of primary virus-derived R5 Envs
that have diversity in ability to enter MDM. Consistent with previous
studies (Peters et al., 2006), many of the R5 Envs displayed very
inefﬁcient entry into MDM compared to controls, conﬁrming that
CCR5-usage of HIV-1 does not predict M-tropism.The magnitude of macrophage entry correlates with increased ability to
utilize low levels of CCR5
Although previous studies have shown that an increased ability to
interact with CD4 contributes to M-tropism of R5 Envs (Duenas-
Decamp et al., 2009; Dunfee et al., 2006, 2007, 2009; Peters et al., 2004,
2008), other studies suggest that an augmented interaction between
gp120 and CCR5may also be important for efﬁcient macrophage entry
(Gorry et al., 2001, 2002; Gray et al., 2005). Therefore, we conducted
experiments using 293-Afﬁnoﬁle cells to determine whether efﬁcient
macrophage entry is associated with an increased ability of Env to
scavenge low levels of cell surface CCR5. Alternative populations of
cells expressing a moderate level of CD4 together with low (CCR5low)
or high (CCR5high) levels of CCR5 were generated (Fig. 2A), and
inoculated with equivalent infectious units of Env-pseudotyped
reporter virus. Although CD4 and CCR5 expression levels on primarymacrophages were inoculated with equivalent amounts of luciferase reporter virus
rials and Methods. Macrophage entry levels were expressed relative to that attained by
04, 2006, 2008). Values represent means from triplicate wells, and are representative of
nt standard error of the mean.
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expression levels in CCR5low cells are within the range of what is
typically observed in primary macrophages (Lee et al., 1999). The
ability of viruses pseudotyped with the primary Envs to enter CCR5low
cells varied considerably (Fig. 2B). When the level of entry in CCR5low
cells was plotted against the level of entry in MDM achieved using the
samepreparations of reporter viruses, we observed a highly signiﬁcant
positive correlation between the magnitude of macrophage entry and
the ability of Env to scavenge low levels of CCR5 (Fig. 2C). Similar
results were obtained using Cf2th-CD4 cells expressing either low or
high levels of CCR5 (data not shown). These results suggest a more
efﬁcient interaction between gp120 and CCR5 by M-tropic Envs.
M-tropic R5 Envs have reduced sensitivity to the CCR5 inhibitor
maraviroc
To further investigate whether the efﬁciency of the gp120-CCR5
interaction inﬂuences M-tropism of R5 Envs, we determined the
sensitivity of Env-pseudotyped luciferase reporter viruses to inhibi-
tion by the CCR5 inhibitor maraviroc (MVC). The IC50 values for MVC
in JC53 cells were determined from virus inhibition curves, and
plotted against the level of MDM entry achieved using the same
preparations of reporter viruses (Fig. 3). We observed a positive
correlation between the ability of Env to enter macrophages and
reduced sensitivity to inhibition by MVC. Consistent with these
results, the M-tropic R5 ADA Env was approximately 5-fold lessFig. 2. Efﬁcient macrophage entry is associated with more efﬁcient use of CCR5. CCR5low an
CCR5, respectively (A), were produced from 293-Afﬁnoﬁle cells (Johnston et al., 2009) andw
described in Materials and Methods. The entry levels in CCR5low cells were expressed as a
triplicate wells, and are representative of 3 independent experiments. Error bars represent s
the level of entry attained by the same preparations of reporter virus in MDM, using Prism
P values are shown. P values b0.05 were considered statistically signiﬁcant. Similar cor
ﬂuorescence.sensitive to inhibition by MVC than the non-M-tropic R5 JR-CSF Env
(data not shown). These results suggest greater competition between
M-tropic Envs and MVC for CCR5 occupancy. Moreover, they indicate
broad variation in the baseline sensitivity of primary R5 Envs to MVC,
which may be clinically important. Together, the results shown in
Figs. 2 and 3 are consistent with a more efﬁcient CCR5 engagement by
M-tropic R5 Envs.
M-tropic Envs have an altered mechanism of CCR5 engagement
More efﬁcient CCR5 usage by M-tropic Envs raises the possibility
that M-tropic Envs have an altered mechanism of coreceptor
engagement. In particular, if the reduced sensitivity of M-tropic
Envs to inhibition byMVC (Fig. 3) is indeed due to greater competition
for CCR5, M-tropic R5 Envs would be expected to have a more
favored- or more critical interaction with the CCR5 ECL2 region.
To determine whether the more efﬁcient CCR5 usage by M-tropic
R5 Envs is linked to an altered mechanism of CCR5 engagement, we
conducted fusion assays using target cells expressing CD4 and either
WT CCR5 or a mutant coreceptor containing amino acid alterations in
the N-terminus, ECL1, ECL2 or ECL3 regions of CCR5 which attenuate
coreceptor activity (Doranz et al., 1997; Farzan et al., 1998), and
effector cells expressing gp120 (Fig. 4). Cell surface staining by ﬂow
cytometry showed similar levels of gp120 expressed on the surface of
effector cells (data not shown), and similar levels of WT or mutant
CCR5 expressed on the surface of target cells (Fig. 4B). We observed ad CCR5high cells expressing moderate levels of CD4 together with low or high levels of
ere inoculated with equivalent amounts of Env-pseudotyped luciferase reporter virus, as
percentage of that attained in CCR5high cells (B). The values shown are means from
tandard deviation. The relative ability of Envs to enter CCR5low cells was plotted against
version 4.0c (GraphPad Software) (C). The Spearman correlation coefﬁcient (r) and
relations were made using data from 5 independent MDM donors. MCF, mean cell
Fig. 3. Efﬁcient macrophage entry is associated with reduced baseline sensitivity of
Envs to the CCR5 antagonist maraviroc. The IC50 values for MVC were determined as
described in Materials and Methods, and plotted against the level of entry attained by
the same preparations of reporter virus in MDM, using Prism version 4.0c (GraphPad
Software). The Spearman correlation coefﬁcient (r) and P values are shown. P values
b0.05 were considered statistically signiﬁcant. Similar correlations were made using
data from 5 independent MDM donors.
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entry and the ability of Env to tolerate mutation of Y15 in the CCR5
N-terminus (Figs. 4A,C). However, we found signiﬁcant inverseFig. 4. Envs with efﬁcient macrophage entry have an altered mechanism of CCR5 engagemen
efﬁciency of MDM entry is shown in (A). The level of WT and mutant CCR5 expression was m
WT CCR5 or CCR5 with mutations at Y15, H181 or Y184 were used in cell-cell fusion assays
Methods. The level of fusion in experiments using a particular CCR5 mutant was expressed
using Prism version 4.0c (GraphPad Software) (C). The values shown are means from tr
correlation coefﬁcient (r) and P values are shown. P values b0.05 were considered statisti
donors.correlations between the magnitude of MDM entry and the ability
of Env to tolerate mutation of H181 or Y184 in the CCR5 ECL2 region
(Figs. 4A,C). These results suggest increased reliance on H181 and Y184
by M-tropic R5 Envs, and a likely reduced reliance on Y15. Further
studieswith greater numbers ofR5 Envs are required todeterminemore
precisely whether Y15 in the CCR5 N-terminus inﬂuencesM-tropism of
HIV-1. Curiously, several Envs with inefﬁcient MDM entry could not
only tolerate ECL2 mutations well, they tended to fuse with cells
expressing the ECL2 mutants more efﬁciently than cells expressingWT
CCR5, particularly the H181A mutant. Whether this observation is
signiﬁcant and/or biologically relevant is uncertain. Mutation of Y14
and D11 in the CCR5 N-terminus abolished coreceptor activity against
all Envs, while no correlations or trends were observed between MDM
entry and the ability of Env to tolerate mutations at Y89 and H88 in the
CCR5 ECL1 region, Q188 and K197 in the CCR5 ECL2 region, and E262
and F264 in the CCR5 ECL3 region (data not shown). Thus, the more
efﬁcient CCR5 usage by M-tropic R5 Envs is linked to an altered
mechanism of CCR5 engagement.
Consistent with our results, previous studies have shown that
gp120 proteins that become less reliant on the CCR5 N-terminus show
greater dependence on the ECL2 region, which in turn promotes
greater afﬁnity for CCR5 (Platt et al., 2001). Moreover, studies with
CCR5 chimeras have shown that primary R5 HIV-1 isolates obtained
from patients with late stage HIV-1 infection, which typically have
reduced sensitivity to inhibition by β-chemokines (Jansson et al.,
1999; Karlsson et al., 2004; Koning et al., 2003; Scarlatti et al., 1997)t. A schematic depicting the location of CCR5 residues that were shown to inﬂuence the
easured by ﬂow cytometry (B). Cells expressing CD4 together with equivalent levels of
with effector cells expressing equivalent levels of gp120, as described in Materials and
as a percentage of that attained using WT CCR5, and plotted against MDM entry levels,
iplicate wells, and are representative of 3 independent experiments. The Spearman
cally signiﬁcant. Similar correlations were made using data from 5 independent MDM
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CCR5 usage (Karlsson et al., 2004). Together, our data and those from
previous studies suggest that R5 Envs with efﬁcient MDM entry have
an altered- and more efﬁcient mechanism of CCR5 engagement,
characterized by a more critical interaction with the CCR5 ECL2
region, and a likely less critical interaction with the CCR5 N-terminus.M-tropic R5 Envs have greater exposure of CD4-induced epitopes in
gp120
Binding of gp120 to CD4 induces exposure of the CCR5 binding site.
To determine whether M-tropic R5 Envs with altered and more
efﬁcient CCR5 usage have greater exposure of CD4-induced (CD4i)
epitopes, we next determined the association between the magnitude
of MDM entry and immunoreactivity of CD4-bound gp120 to the
monoclonal antibodies 17b and 48d, which recognize distinct CD4i
epitopes in the gp120 core overlapping the CCR5 binding site (Kwong
et al., 1998; Moore et al., 1993; Thali et al., 1993). We observed
positive correlations between the magnitude of MDM entry and the
ability of CD4-bound gp120 to recognize 17b (Fig. 5A) and 48d
(Fig. 5B). None of the Envs recognized 17b or 48d in the absence of
soluble CD4 (data not shown), suggesting that M-tropic R5 Envs do
not have CD4-independent exposure of the coreceptor binding site in
gp120. Equivalent reactivity to the polyclonal HIV-1 sera BB10, which
strongly recognises gp120 (Gorry et al., 1999), indicated equivalent
levels of cell-surface Env expression (data not shown). In addition, we
saw no correlation between MDM entry and the ability of gp120 to
bind the V3-speciﬁc monoclonal antibody 39F (Kwong et al., 2002;
Pantophlet et al., 2004) (data not shown), which recognizes a linear
epitope on the ascending (N-terminal) strand of the V3 loop.
Together, these results provide evidence that greater exposure of
the CD4-induced coreceptor binding site in gp120 contributes to the
more efﬁcient CCR5 usage by M-tropic R5 Envs.
The coreceptor binding site in gp120 is formed by dramatic
conformational changes that are triggered by CD4 binding (Chen et al.,
2005; Kwong et al., 1998; Myszka et al., 2000). The 17b mAb binds to a
small (∼500 Å2) basic surface area of gp120 via the highly protruding
acidic complementarity determining region (CDR) H3 loop, as well as a
hydrophobic interaction between a CDR H2 loop of 17b and the gp120
bridging sheet (Huang et al., 2004; Kwong et al., 1998, 2000). The
relatively small interface area and protruding CDR H3 loop paratope of
17b is likely to be the result of limited accessibility of the coreceptor
binding site. Enhanced binding of 17b by M-tropic Envs may be due toFig. 5. Efﬁcient macrophage entry is associated with greater exposure of CD4-induced epitop
(A) and 48d (B) was determined by ﬂow cytometry, as described in Materials and Methods
control R5 Env ADA, and plotted against MDM entry levels using Prism version 4.0c (Graph
independent experiments. The Spearman correlation coefﬁcient (r) and P values are shown.
using data from 5 independent MDM donors.electrostatic interactions with 17b CDR loops or protection of
hydrophobic residues to result in a higher afﬁnity interaction. Thus,
structural alterations in gp120 that result in greater exposure of CD4i
epitopeswithin the coreceptor binding sitemay contribute to enhanced
MDM entry and more efﬁcient CCR5 usage by R5 Envs.A more efﬁcient gp120-CCR5 interaction may occur through a variety of
structural mechanisms
To better understand the structural basis of efﬁcient CCR5 usage
and MDM entry by M-tropic R5 Envs, we compared three paired Env
sequence sets that had consistent differences in levels of M-tropism
when tested in ﬁve independent MDM donors, despite being cloned
from the same primary virus isolates (Table 1). Thus, we took
advantage of the fact that a similar genetic background would help
pinpoint Env amino acid alterations that may contribute to efﬁcient
MDM entry.
Molecular models of the Env pairs were produced to examine
sequence changes in the context of predicted three-dimensional
gp120 structures. Sequence analysis together with models based on
the 2B4C crystal structure of the V3 loop-containing, CD4-liganded
gp120 showed that, in NB24 clones, alterations associated with more
efﬁcient MDM entry were located predominantly within- or immedi-
ately adjacent to the V3 loop (Fig. 6A). Interestingly, NB24-C3 Env
which enters MDM very inefﬁciently, was more sensitive to mutation
of Y15 in the CCR5 N-terminus compared to NB24-C4 Env (data not
shown), consistentwith the overall trend observed between increased
M-tropism and reduced dependence on Y15 (Fig. 4C). In NB24-C3,
changes in the G-P-G-R/K motif at the tip of the V3 loop, which is
highly conserved among clade B Envs (Plantier et al., 1999), may
contribute to the reduced tolerance of mutation in the N-terminus of
CCR5 compared to NB24-C4 by abrogating the interaction with
negatively charged sulfate groups of sulfotyrosine residues.
Using the recently-described 3JWO crystal structure of gp120
containing the gp41 interactive domain (Pancera et al., 2010) to
model amino acid substitutions, we showed that an R5 Env pair that
displayed signiﬁcant disparity in M-tropism contained alterations in
the gp41 interface region within gp120 (Fig. 6B). All but one amino
acid substitution between NB2-C1 and NB2-C4 Envs were located
within or near sites in the C1 and C5 regions of gp120 that have been
shown by mutagenesis to interact with the gp41 fusion protein
(Helseth et al., 1991; Pancera et al., 2010; Sen et al., 2008; Yang et al.,
2003). Transmission of an activation signal from the CD4/coreceptor-es in gp120. Immunoreactivity of CD4-bound gp120 to the monoclonal antibodies 17b
. The level of antibody binding was expressed as a percentage of that achieved for the
Pad Software). The values shown are means of triplicates, and are representative of 3
P values b0.05 were considered statistically signiﬁcant. Similar correlations were made
Table 1
Paired Env clones with variable relative levels of M-tropism.
Env clone Primary virus
isolate
Relative level of
MDM entry
Genbank accession
number
NB24-C3 NB24 - EU308561
NB24-C4 ++ EU308562
NB2-C1 NB2 - EU308541
NB2-C4 ++ EU308543
NB23-C2 NB23 ++ EU308557
NB23-C3 +++ EU308558
MDMentry of primary R5Envswas scored as– (≤0.5-fold relative entry),+(0.5- to2-fold
relative entry), ++ (2- to 10-fold relative entry), and +++ (≥ 10-fold relative entry).
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gp120-gp41 interface (Chan et al., 1997; Melikyan et al., 2000; Tan
et al., 1997; Weissenhorn et al., 1997). Mutations in these regions
have been shown to modulate gp120-gp41 association (Helseth et al.,
1991; Sen et al., 2008; Yang et al., 2003), including the valine residue
at position 496 in C5 (Sen et al., 2008), which differs between NB2-C1
and NB2-C4 Envs. These observations suggest that some R5 Envs may
become more efﬁcient at utilising CCR5 by way of altered transmis-
sion of gp120 signalling events to the gp41 fusion peptide.
While coreceptor interaction or subsequent signal transduction
pathways may contribute to efﬁcient MDM entry by certain R5 Envs,
others may indirectly have an enhanced interaction with CCR5 via a
more efﬁcient interaction with CD4, as suggested by previous studies
using particular neurotropic R5 Envs (Dunfee et al., 2006). For
example, the gp120-CD4 interaction is short-lived andweak compared
to the interaction between CD4-bound gp120 and CCR5 (Chang et al.,
2005). Since CCR5 is more mobile in the cell membrane than CD4
(Steffens and Hope, 2004), a more stable gp120-CD4 interaction by R5
Envs could potentially allow the Env-CD4 complex tomore readily co-
localize with CCR5, thus increasing the efﬁciency of CCR5 usage. This
possibility is illustrated by comparing the predicted gp120 structures
of NB23-C2 and NB23-C3 Envs. In addition to loss of a potential
glycosylation site in V1, NB23-C2 Env contains a rare aspartic acid to
glycinemutation at position 477 near the CD4bswhenmodeled on the
2B4C gp120 crystal structure (Fig. 6C).Whenmapped to the surface of
gp120, Asp477 increases the local negative charge and may play an
important role in maintaining electrostatic interactions between the
predominantly negatively charged CD4bs on gp120 and the predom-
inantly positively charged binding site on the CD4 molecule.
Together, these analyses provide evidence that more efﬁcient
CCR5-usage that contributes to M-tropism of R5 HIV-1 strains, may be
gained through different structural mechanisms. Speciﬁcally, primary
R5 Envs may acquire enhanced MDM entry by changing the way they
interact with CCR5, by improving the efﬁciency by which signals are
transmitted to the gp41 fusion peptide, or by augmenting the
interaction with CD4 and thus reducing the reliance on high levels
of CCR5 to mediate fusion and entry. Further mutagenesis studies are
required to fully elucidate the biological role of Env amino acid
alterations associatedwithmore efﬁcient CCR5 usage andMDMentry.Conclusions
In summary, we showed that the efﬁciency of MDM entry by R5
Envs is linked to a more efﬁcient and altered mechanism of CCR5
engagement characterized by increased dependence on speciﬁc amino
acids in the CCR5 ECL2 region, at least among the panel of primary Env
clones studied. Furthermore, greater exposure of CD4i gp120 epitopes
overlapping the coreceptor binding site among M-tropic R5 Envs
provided evidence that structural alterations in CD4-bound gp120
augment gp120-CCR5 interactions and contribute to efﬁcient MDM
entry. Finally, sequence analysis together with molecular modeling of
gp120 suggests that enhanced gp120-CCR5 interactions may contrib-ute to M-tropism of R5 HIV-1 strains through different structural
mechanisms.
Materials and Methods
Plasmids
TheHIV-1 Envs used in this studywere cloned fromprimary R5HIV-1
isolates which have been described in detail previously, including the
clinical characteristics of the subjects from whom they were isolated
(Gray et al., 2005; Li et al., 1999). The Env clones used were NB23-C2,
NB23-C3, NB24-C3, NB24-C4, NB25-C2, NB25-C3, NB27-C2, NB27-C3,
NB2-C1, NB2-C4, NB6-C3, NB6-C4, NB7-C1, NB7-C2, NB8-C1, NB8-C2 and
NB8-C4, which have been described in detail previously (Sterjovski et al.,
2007) (accession numbers EU308533 to EU308568). Brieﬂy, the 2.1Kb
KpnI-to-BamHI fragment of the HIV-1 env genewas ampliﬁed from virus
isolates and cloned into the pSVIII-Env expression vector (Gao et al.,
1996), as described previously (Gray et al., 2006, 2009; Sterjovski et al.,
2007). The pcDNA3-CD4 and pcDNA3-CCR5 plasmids express human
CD4 and CCR5, respectively (Gorry et al., 2001). pSVL-Tat expresses the
HIV-1 Tat protein. The CCR5 mutants used in this study have been
described previously (Doranz et al., 1997; Farzan et al., 1998).
Cells
Cf2-Luc cells (Etemad-Moghadam et al., 2000), derived from the
Cf2th canine thymocyte cell line (Choe et al., 1996), stably express the
luciferase gene under the control of the HIV-1 long terminal repeat
and were cultured in Dulbecco modiﬁed Eagle medium (DMEM)
supplemented with 10% (vol/vol) fetal calf serum (FCS), 100 µg of
penicillin and streptomycin per ml, and 0.7 mg of G418 per ml. 293 T
cells were cultured in DMEM supplemented with 10% (vol/vol) FCS,
and 100 µg of penicillin and streptomycin per ml. JC53 cells are
derived from the HeLa cell line and stably express high levels of CD4,
CXCR4 and CCR5 on the cell surface (Platt et al., 1998), and were
cultured in DMEM supplemented with 10% (vol/vol) FCS, and 100 µg
of penicillin and streptomycin per ml. Peripheral blood mononuclear
cells (PBMC) were puriﬁed from the blood of healthy HIV-1 negative
donors by density gradient centrifugation. Monocyte-derived macro-
phages (MDM) were produced from elutriated monocytes (from
PBMC) that were cultured for 5 days in RPMI 1640 medium
supplemented with 10% (vol/vol) pooled human sera, 100 µg of
penicillin and streptomycin per ml, and 12.5 ng of macrophage
colony-stimulating factor per ml. The dually-inducible 293-Afﬁnoﬁle
cell line (Johnston et al., 2009), in which expression of CD4 and CCR5
can be induced and regulated by the addition of minocycline or
ponasterone A (ponA), respectively, was maintained in DMEM
supplemented with 10% (vol/vol) FCS, 100 µg of penicillin and
streptomycin per ml, and 50 µg blasticidin per ml. To produce cell
populations expressing a moderate level of CD4 together with low
(CCR5low) or high (CCR5high) levels of CCR5, 293-Afﬁnoﬁle cells were
treated with 1.25 ng/ml minocycline together with 0 or 2.0 µM ponA,
respectively. Note that in 293-Afﬁnoﬁle cells there is low level basal
CCR5 expression without induction by ponA (Pugach et al., 2009), so
cells were treated with minocycline alone to produce the CCR5low
population.
Binding assays
Detection of ligand binding to gp120 expressed on the surface of
293 T cells was carried out using ﬂow cytometry. 293 T cells were
transfected with Env expression plasmids using Lipofectamine 2000
(Invitrogen) according to the manufacturers’ protocol, and stained for
surface gp120 expression using pooled polyclonal HIV+sera BB10, as
described previously (Sterjovski et al., 2007). Approximately 2 x 105
293 T cells transfectedwith each Env expression plasmidwere used in
Fig. 6. Several structural mechanisms could potentially enhance the interaction between M-tropic Envs and CCR5. A subset of Envs contain changes in the V3 loop of gp120 which may
contribute toM-tropism (A). The V3 region (boxed) of NB24-C3 andNB24-C4 Envswas aligned against theM-tropic R5 JR-FL Env (A, top panel). Amino acid sequence is colored according
to polarity: Polar, green; Non-polar, black; Positively-charged, blue; Negatively charged, red. Potential N-linked glycosylation sites are marked by , and grey circles mark the position of
residues that have previously been shown bymutagenesis to be important for coreceptor binding (Cormier and Dragic, 2002; Rizzuto et al., 1998; Suphaphiphat et al., 2007). Amino acid
differences in the V3 loop of NB24 Envs were analyzed in the context of their predicted three-dimensional structures that were generated using the V3-containing JRFL crystal structure
(2B4C) (Huang et al., 2005) (A). Residues that differed betweenNB24Envs are shown in stick representation and colored as in the sequence alignment, with van derWaals surface in grey.
The gp120 structures are shown in grey ribbon representation with the V3 loop in gold and the bridging sheet in magenta. In (B), the Envs derived from virus NB2, which displayed
signiﬁcant disparity in M-tropism, contained changes in the gp41-interractive region of gp120. Regions within the N-terminus (residues 75 to 97) and C-terminus (residues 493 to 501)
that contained amino acid changes were aligned (B, top panel), grey circles mark the position of residues that have previously been shown by mutagenesis to be involved in gp41
interaction (Pancera et al., 2010). The gp120 structure containing the gp41 interactive domain (Protein Data Bank ID: 3JWO, (Pancera et al., 2010)) is shown in ribbon representation
(B, bottompanel), with the inner and outer domains colored in light and dark grey, respectively. Residues involved in gp41 interaction are shown in grey stick representation, and residues
that differ betweenNB2-C1 andNB2-C4 are shown inblue stick representation,with those that occur at positions involved in gp41 interaction highlightedwith grey van derWaals surface.
The stemof the V3 loop is colored gold. In (C), themolecular surface of the predicted structures of NB23-C2 (C, left) and NB23-C3 (C, center) Envs and of CD4 (C, right) are shownwith the
gp120-CD4 interface highlighted in grey. Basic, acidic and polar uncharged residues found at the interface are colored blue, red and green, respectively. The location of theG477Dmutation
is shown in the sequence alignment (C, top left); grey circles mark the position of residues previously shown to be involved in CD4 binding (Kwong et al., 1998; McCaffrey et al., 2004).
275J. Sterjovski et al. / Virology 404 (2010) 269–278binding reactions. In 17b and 48d binding reactions, cells were pre-
incubated in FACS buffer [phosphate buffered saline (PBS) containing
10% (vol/vol) FCS and 0.05% (wt/vol) sodium azide] with or without
1 µg of sCD4 per ml (Progenics Pharmaceuticals Inc., Tarrytown, NY)for 1 h at room temperature. Cells were then washed twice with 1 ml
FACS buffer and resuspended in 50 µl of FACS buffer containing 20 µg
of 17b (Kwong et al., 1998; Sullivan et al., 1998; Thali et al., 1993;
Trkola et al., 1996; Wyatt et al., 1995, 1998) or 48d (Moore et al.,
276 J. Sterjovski et al. / Virology 404 (2010) 269–2781993; Thali et al., 1993) perml. These concentrationswere empirically
determined to be within the linear range of binding (data not shown).
Following incubation for 1 h at room temperature, cells were washed
twice with 1 ml FACS buffer and resuspended in 50 µl of FACS buffer
containing a 1:200 dilution of FITC-conjugated anti-human IgG F(Ab)2
fragment (Millipore Corporation, Billerica, MA). Cells were incubated
for 1 h at room temperature prior to being washed twice with 1 ml of
FACS buffer and resuspended in 150 µl of PBS containing 4% (wt/vol)
paraformaldehyde, and analysed by ﬂow cytometry as described
previously (Gorry et al., 1999).
Fusion assays
Cell-cell fusion assays were conducted as described previously
(Sterjovski et al., 2007). Brieﬂy, Cf2-Luc target cells seeded in 25 cm2
tissue culture ﬂasks were transfected with 1 µg of CD4 plasmid and or
3 µg of wild-type (WT) or mutant CCR5 plasmid. 293 T effector cells
seeded in 6-well tissue culture plateswere co-transfectedwith 3.4 µg of
Env-expressing plasmid and 0.6 µg pSVL-Tat. Target and effector cells
were transfected using Lipofectamine 2000 (Invitrogen) according to
the manufacturers’ protocol. Approximately 2.5×104 293 T effector
cells were added to 2.5×104 Cf2-Luc target cells. After mixing, target
and effector cells were incubated at 37 °C in replicate wells containing
200 µl of culture medium. Cells from replicate wells were harvested at
10 h post-mixing and assayed for luciferase activity (Promega)
according to the manufacturers’ protocol. Luminescence was measured
using a FLUOStar microplate reader (BMG LABTECH, GmbH, Germany).
293 T cells transfected with pSVL-Tat alone were used as negative
controls to determine the background level of luciferase activity.
Production and quantitation of Env-pseudotyped, luciferase reporter
viruses
Env-pseudotyped, luciferase reporter viruses were produced by
transfection of 293 T cells with pCMVΔP1ΔenvpA, pHIV-1Luc and
pSVIII-Env plasmids using Lipofectamine 2000 (Invitrogen) at a ratio
of 1:3:1, as described previously (Gray et al., 2006; Sterjovski et al.,
2007; Yang et al., 2001). Supernatants were harvested 48 h later,
ﬁltered through 0.45 µm ﬁlters and stored at -80 °C. The TCID50 of
virus stocks was determined by titration in JC53 cells (Platt et al.,
1998), as described previously (Gray et al., 2009; Sterjovski et al.,
2007).
HIV-1 Entry assays
For entry assays using JC53 cells or 293-Afﬁnoﬁle cell populations,
2×104 cells were inoculated with 200 TCID50 of Env-pseudotyped
luciferase reporter virus (equating to a multiplicity of infection [MOI]
of 0.01) in a volume of 100 µl for 12 h at 37 °C. The cells were washed
twice with culture medium to remove residual inoculum and
incubated for a further 60 h at 37 °C. For entry assays in MDM,
5×104 cells were inoculated with 500 TCID50 of Env-pseudotyped
luciferase reporter virus (equating to an MOI of 0.01) in a volume of
100 µl for 12 h at 37 °C. The cells were washed twice with culture
medium to remove residual inoculum and incubated for a further 96 h
at 37 °C. In all cell types, the level of HIV-1 entry was measured by
luciferase activity in cell lysates (Promega), according to the
manufacturers’ protocol. Luminescence was measured using a
FLUOStar microplate reader (BMG LABTECH, GmbH, Germany).
Negative controls included mock-infected cells that were incubated
with culture medium instead of virus, and cells inoculated with
luciferase reporter virus pseudotyped with the non-functional ΔKS
Env (Etemad-Moghadam et al., 2000). Macrophage entry levels were
normalized against that attained by the same preparations of reporter
virus in JC53 cells to more accurately control for virus infectivity, as
described previously (Peters et al., 2004, 2006, 2008). In experimentsmeasuring the inhibition of HIV-1 entry by maraviroc (MVC) in JC53
cells, the cells were left untreated or preincubated with serial 5-fold
dilutions of drug for 30 min prior to inoculation with virus (0.064 to
1000 nM). The drug concentrations were maintained during the virus
inoculation and the subsequent culture period. After the background
activity was subtracted, the amount of luciferase activity in cells
treated with MVC was expressed as a percentage of that in untreated
cells. The percent inhibition was calculated by subtracting this
number from 100. Data were ﬁtted with a nonlinear function, and
50% inhibitory concentrations (IC50) were calculated by least squares
regression analysis of inhibition curves, as described previously
(Gorry et al., 2002, 2007; Gray et al., 2005; Sterjovski et al., 2007).
Computer-aided structure prediction of gp120
Homology models of CD4-bound and primary gp120 sequences
were prepared using the Build Model protocol of the Discovery Studio
suite, version 1.6 (Accelrys, San Diego, CA, USA). This approach uses
the Modeller algorithm to generate an atomic model of the target
protein from a template molecule and a sequence alignment. The
template-basedmodels are optimised by iterative cycles of conjugate-
gradient minimisation against a probability density function that
includes spatial restraints derived from the template and residue
speciﬁc properties (Sali and Blundell, 1993). The crystal structure of
JRFL gp120 containing the V3 variable loop and bound to CD4 and the
X5 Fab antibody fragment was used as the template for CD4-bound
models (Protein Data Bank ID: 2B4C; (Huang et al., 2005)). The X5
antibody fragment was deleted from the CD4-bound template prior to
modeling. The coordinates for gp120 and CD4 were extracted from
the 2B4C crystal structure. Sequence alignments were generated
between JRFL gp120 and the primary gp120 Env clones. The sequence
for CD4 was included as a second polypeptide chain such that the
models of gp120were constructed as complexes with CD4. The V1/V2
variable loops were replaced with a GAG linker sequence and the
N- and C- termini overhangs were cut using the modeling software.
Similarities in three-dimensional structure were measured by the
root mean square deviation (RMSD) of the distances between main-
chain atoms (N, Cα, C andO atoms) from crystal andmodel structures
after rigid body superposition, where an RMSD of b1 Å signiﬁes a
high level of homology of three-dimensional structure between
overlayed proteins. The overall quality of the geometry of gp120
models generated was veriﬁed using PROCHECK (Laskowski et al.,
1993). Additional energy minimisation using the Crystallography
and Nuclear Magnetic Resonance System (CNS) program package
(Brunger et al., 1998) did not further improve the geometry of model
structures or lower the RMSD.
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